Innate Pharma

Innate Pharma, S.a.

Bristol-myers Squibb Compnay

Novo Nordisk A/s

University of Genova

Universita Di Genova

Mathieu Blery

Pascale Andre

Carine Paturel

Nicolai Wagtmann

Caroline Soulas

Laurent Gauthier

Nadia Anceriz

Hélène Sicard

Renaud Buffet

Cecile Bonnafous

Cécile Bonnafous

Alessandro Moretta

Ashok Kumar Gupta

Francois Romagne

Petrus Johannes Louis Spee

Ivan Perrot

François Romagne

Michael Darron Robbins

Nicolaï Wagtmann

Ulrik Morch

Luisa M Salter-Cid

Caroline Denis

The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

NKp46 binding agents

The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

Treatment regimens using anti-NKG2A antibodies

The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

Treatment of peripheral T cell lymphoma

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

Neutralization of inhibitory pathways in lymphocytes

The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

Treatment of cancers using anti-NKG2A agents

This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.

The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

Mica binding agents

Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.

Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.

Compositions and methods for treating proliferative disorders

Growing community of inventors

Marseilles, France

Mathieu Blery